SeraCare Life Sciences, a manufacturer and leading partner to global in vitro diagnostics manufacturers and clinical laboratories, today announced that Joe Bernardo has joined SeraCare’s board of directors in the role of Chairman. Mr. Bernardo is also an Operating Partner at Linden Capital Partners who are the equity investors behind SeraCare Life Sciences.
The decision matrix for liquid biopsies is defined by the sample, method, the analysis platform, and the desired output.
Truth-set NGS reference materials to significantly advance validation and QC of myeloid assays
NEW YORK (GenomeWeb) – Stakeholders in the liquid biopsy field gathered yesterday to discuss the state of the science for blood-based cancer genomics, to quantify the challenges facing test developers and regulators, and to discuss ongoing projects and new data.
To ensure the accuracy of patient testing results, clinical next-generation sequencing (NGS) labs must track metrics across their assay’s workflow to determine whether runs were within established limits.
Comprehensive suite of Zika IgM and recombinant Zika virus reference materials for method validation and evaluation of serological and molecular infectious disease assays.
SeraCare Life Sciences, Milford, Mass, has launched Seraseq Circulating Tumor DNA v2 reference materials, aimed to closely mimic the performance attributes of ctDNA derived from clinical specimens.
NEW YORK (GenomeWeb) – As liquid biopsy genetic tests have rocketed into clinical practice over the last handful of years, clinical researchers, test developers, and others have begun to pay increasing attention to a relative lack of tools to ensure assays are validated and performed according to common, or at least equivalent standards.
The lack of adequate circulating tumour DNA reference materials for developing and measuring safe, accurate, and reproducible assays continues to be a challenge for clinical labs.
Clinical labs are adopting next-generation sequencing technology at ever increasing rates.
Research presented at ASM Microbe 2017 by experts at the Fertility and Cryogenics Lab shows a reliable clinical assay that can detect the Zika virus from semen samples.
New Orleans, LA – June 4, 2017 – Research presented at ASM Microbe 2017 by experts at the Fertility and Cryogenics Lab shows a reliable clinical assay that can detect the Zika virus from semen samples.
SeraCare Life Sciences features in Genetic Engineering & Biotechnology News: Think of cancer as criminal activity, and you'll understand the need to properly secure evidence from liquid biopsies.
NEW YORK (GenomeWeb) – SeraCare Life Sciences has announced a collaboration with the US National Institute of Standards and Technology (NIST) to develop circulating tumor DNA (ctDNA) reference standard materials for diagnostics.
SeraCare Life Sciences, Milford, Mass, has launched the AccuPlex Zika reference material to fast-track the development and validation of polymerase chain reaction (PCR)-based Zika virus assays.
SeraCare Life Sciences has launched AccuPlex Zika Reference Material, which is designed to fast-track the development and validation of PCR-based Zika virus assays
SeraCare and Toma Bio have developed a solid tumor gene analysis kit. — GenomeWeb
SeraCare Life Sciences, a manufacturer and leading partner to global in vitro diagnostics manufacturers, today announces the launch of two new circulating tumor DNA (ctDNA) products at the 2016 Molecular Medicine Tri-Conference in San Francisco.
NEW YORK (GenomeWeb) – SeraCare Life Sciences today announced a licensing agreement with the University of California, San Francisco for the use of its trisomy 21, 18, and 13 trophoblast cell line materials to develop reference materials for non-invasive prenatal testing of chromosomal abnormalities.
The new precision medicine business unit of SeraCare Life Sciences, Milford, Mass, has launched its first product, the Seraseq solid tumor mutation mix I.
Select your country.
